Find a Trial

Trial Results


15 protocol(s) meet the specified criteria
20170543OPEN TO ACCRUAL
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.
A081105OPEN TO ACCRUAL
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
BTCRC-LUN17-139OPEN TO ACCRUAL
CTO-LUN18-335OPEN TO ACCRUAL
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
IUSCC-0580OPEN TO ACCRUAL
Blood Based Recurrence Detection for Patients with Lung Cancer Receiving Radiation Therapy
IUSCC-0624OPEN TO ACCRUAL
Phase I/II trial evaluating five fraction SABR dose escalation for early stage Squamous Cell Carcinoma of the Lung
IUSCC-0695OPEN TO ACCRUAL
Survey of Health and Well-Being in Advanced Cancer Patients
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
LUN17-302OPEN TO ACCRUAL
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
LUN17-321OPEN TO ACCRUAL
A Phase II study of Concurrent Chemoradiation plus Durvalumab followed by Surgery followed by Adjuvant Durvalumab in medically operable patients with surgically resectable Stage IIIA (N2) Non-Small Cell Lung Cancer